Dyne Therapeutics (DYN) Other Operating Expenses (2021 - 2026)
Dyne Therapeutics (DYN) posted quarterly Other Operating Expenses of -$88000.0 for Q2 2026, up 94.49% year-over-year from -$45246.6 in Q2 2025, and up 33.83% quarter-over-quarter from -$133000.0 in Q1 2026.
Powered by 
Analysis
Dyne Therapeutics (DYN) Other Operating Expenses (2021 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has reported Other Operating Expenses for 6 consecutive years, with -$88000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Operating Expenses rose 94.49% year-over-year to -$88000.0; the TTM figure through Jun 2026 stood at -$231000.0 (up 90.59% YoY), while the FY2025 annual figure was -$1.7 million, down 273.79% from the prior year.
- Other Operating Expenses rose to -$88000.0 in Q2 2026 per DYN's latest filing, from -$133000.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $506000.0 in Q1 2024 and bottomed at -$1.6 million in Q2 2025.
- Historically, Other Operating Expenses has averaged -$213333.3 across 5 years, with a median of -$107500.0 in 2023.
- Annual changes were most pronounced in 2023 — Other Operating Expenses plunged 3830.0% — and 2024, when it surged 334.26%.
- Dyne Therapeutics' Other Operating Expenses stood at -$24000.0 in 2022, then tumbled by 2820.83% to -$701000.0 in 2023, then surged by 96.29% to -$26000.0 in 2024, then sank by 1011.54% to -$289000.0 in 2025, then surged by 69.55% to -$88000.0 in 2026.
- Business Quant data shows DYN's Other Operating Expenses at -$88000.0 in Q2 2026, -$133000.0 in Q1 2026, and -$289000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 10 | Dyne Therapeutics | 4.04 Bn | 4.04 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -88,000.00 |
| Mar 31, 2026 | -133,000.00 |
| Dec 31, 2025 | -289,000.00 |
| Sep 30, 2025 | 279,000.00 |
| Jun 30, 2025 | -1.60 Mn |
| Mar 31, 2025 | -89,000.00 |
| Dec 31, 2024 | -26,000.00 |
| Sep 30, 2024 | -742,000.00 |
| Jun 30, 2024 | -192,000.00 |
| Mar 31, 2024 | 506,000.00 |
| Dec 31, 2023 | -701,000.00 |
| Sep 30, 2023 | -126,000.00 |
| Jun 30, 2023 | -373,000.00 |
| Mar 31, 2023 | -216,000.00 |
| Dec 31, 2022 | -24,000.00 |
| Sep 30, 2022 | -9,000.00 |
| Jun 30, 2022 | 10,000.00 |
| Mar 31, 2022 | -30,000.00 |
| Dec 31, 2021 | -8,000.00 |